2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Chevon M. Rariy, MD, director of the Telehealth Program at Cancer Treatment Centers of America (CTCA), to discuss the rapid uptake of telemedicine and virtual health care for patients with cancer during the COVID-19 pandemic and the potential for in-home infusions to further bridge gaps in access to care for patients being treated with chemotherapy.
In 2021, CTCA announced that they were partnering with Coram, CVS Health’s infusion care business, to deliver in-home chemotherapy infusions to eligible patients. Currently, the pilot program is enrolling Atlanta-based patients with a range of diseases, including breast, lung, prostate, colorectal, head and neck, and some genitourinary cancers, but is planned for expansion to other parts of the United States, Rariy explained.
In our exclusive interview, Rariy discussed how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.